Presentation is loading. Please wait.

Presentation is loading. Please wait.

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis.

Published byRandell Wilson Modified over 8 years ago

Similar presentations

Presentation on theme: "Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis."— Presentation transcript:

1 Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Neil P. Shah, John M. Nicoll, Bhushan Nagar, Mercedes E. Gorre, Ronald L. Paquette, John Kuriyan, Charles L. Sawyers Cancer Cell Volume 2, Issue 2, Pages 117-125 (August 2002) DOI: 10.1016/S1535-6108(02)00096-X

2 Figure 1 Cancer Cell 2002 2, 117-125DOI: (10.1016/S1535-6108(02)00096-X)

3 Figure 2 Cancer Cell 2002 2, 117-125DOI: (10.1016/S1535-6108(02)00096-X)

4 Figure 3 Cancer Cell 2002 2, 117-125DOI: (10.1016/S1535-6108(02)00096-X)

5 Figure 4 Cancer Cell 2002 2, 117-125DOI: (10.1016/S1535-6108(02)00096-X)

Download ppt "Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis."

Similar presentations

The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug Resistance in Chronic Myeloid Leukemia Lars Klemm, Cihangir Duy, Ilaria Iacobucci, Stefan.

The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug Resistance in Chronic Myeloid Leukemia Lars Klemm, Cihangir Duy, Ilaria Iacobucci, Stefan.
Lessons from Hereditary Colorectal Cancer

Lessons from Hereditary Colorectal Cancer

Here are some CML slides that may be helpful for your presentation.

Here are some CML slides that may be helpful for your presentation.
Cancer Metabolism Cell Volume 148, Issue 3, (February 2012) DOI: 10.1016/j.cell.2012.01.031 Copyright © 2012 Terms and Conditions Terms and Conditions.

Cancer Metabolism Cell Volume 148, Issue 3, (February 2012) DOI: /j.cell Copyright © 2012 Terms and Conditions Terms and Conditions.
Gleevec vs. BMS Druker vs. Sawyers

Gleevec vs. BMS Druker vs. Sawyers
Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages 275-291 (March 2014) DOI: 10.1016/j.stem.2014.02.006.

Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem
Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia Tim C.P. Somervaille, Michael L. Cleary Cancer Cell.

Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia Tim C.P. Somervaille, Michael L. Cleary Cancer Cell.
Chronic myelogenous leukemia Uncommon disease Highly lethal when ineffectively Rxd Most pts are in their 50s+60s The molecular understanding of this disease.

Chronic myelogenous leukemia Uncommon disease Highly lethal when ineffectively Rxd Most pts are in their 50s+60s The molecular understanding of this disease.
What we will review this lecture: Receptor Tyrosine Kinase signalling: PI3K Pathway – AKT, PDK1, PTEN RTK Signalling in Cancer Historical description of.

What we will review this lecture: Receptor Tyrosine Kinase signalling: PI3K Pathway – AKT, PDK1, PTEN RTK Signalling in Cancer Historical description of.
Genetic testing for high-risk colon cancer patients1 William M. Grady Gastroenterology Volume 124, Issue 6, Pages 1574-1594 (May 2003) DOI: 10.1016/S0016-5085(03)00376-7.

Genetic testing for high-risk colon cancer patients1 William M. Grady Gastroenterology Volume 124, Issue 6, Pages (May 2003) DOI: /S (03)
Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm Thierry Soussi, Klas G. Wiman Cancer Cell Volume 12, Issue 4, Pages 303-312 (October.

Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm Thierry Soussi, Klas G. Wiman Cancer Cell Volume 12, Issue 4, Pages (October.
Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy  Stefania Aliano, Gabriella Cirmena, Giuseppina.

Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy  Stefania Aliano, Gabriella Cirmena, Giuseppina.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Resistance in the land of molecular cancer therapeutics

Resistance in the land of molecular cancer therapeutics
ETV6-NTRK3—Trk-ing the primary event in human secretory breast cancer

ETV6-NTRK3—Trk-ing the primary event in human secretory breast cancer
Charles Swanton, Julian Downward  Cancer Cell 

Charles Swanton, Julian Downward  Cancer Cell 
Inhibitor of MAP kinase activation blocks colon cancer growth

Inhibitor of MAP kinase activation blocks colon cancer growth
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Volume 100, Issue 1, Pages (January 2000)

Volume 100, Issue 1, Pages (January 2000)

Similar presentations

Ads by Google